All News

Article

New Gout Therapies Show Promise in Phase III Trials

ACR Press Release Oct 26, 2025

At ACR Convergence 2025, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices or uncontrolled disease.

Article

ACR Convergence 2025 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases

ACR Press Release Oct 26, 2025

At ACR Convergence 2025, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. Studies presented at the meeting highlighted issues ranging from kidney transplant outcomes in lupus to medication disparities in rheumatoid arthritis and demographic patterns in systemic sclerosis and axial spondyloarthritis.

Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months. Most adverse events were mild (e.g., transaminitis 14.5%) and manageable. No serious infections or MACE reported. A cost-effective alternative to bDMARDs in https://t.co/JBHfNq7kYt

https://x.com/synovialjoints/status/1982530167512932518/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Upadacitinib in GCA doesn't just affect IL-6, it alters IFNg, known to be important in vascular change in GCA. If UPA in GCA has some cardiovascular concerns extrapolated from RA, it also has some plausible cardiovascular benefits too that TCZ may not #ACR25 ABST0751 @RheumNow https://t.co/rMetLPP9z6

https://x.com/drdavidliew/status/1982525324610228517/photo/1

A closer look in skin toxicity of GCs in RMDs GC Toxicity Index, LONG TOX prospective cohort Frequent: -Easy bruising 35% -Atrophy 22% -Hirsutism 17% -Acneiform rash 15% -Erosion/Tear 12% GC-related Neuropsychiatric toxicity highly associated with/ skin, something to look out https://t.co/NfxG8JkxSP

Nice SRMA evaluating HCQ dosing >5mg/kg associated w/3.8x risk of retinopathy... ...but <5mg/kg associated w/1.8x risk of SLE flares Morbidity from one of those is easily avoided by regular screening; morbidity from the other can be devastating @RheumNow #ACR25 Abstr#805 https://t.co/1vJXxXqiRC

https://x.com/EBRheum/status/1982522869562364407/photo/1

PD-1+ effector memory T cells in PsA synovium are functionally active and regulate Th17 cytokines via STAT3/RORγt. Recombinant PD-L1 agonist significantly reduced T cell proliferation and IL-17A/F/IL-22 production highlighting checkpoint agonists as a novel therapeutic strategy https://t.co/I6eNa0j7aa

https://x.com/synovialjoints/status/1982522619220898224/photo/1

What is #nonadherence in #SLE associated with? 115 Pts w #lupus in Spain Overall medication adherence 58%! 👇Reduced if Male Low education No partner -NS adjusted analysis Unemployed Comorbidities 3 or more drugs/pills -NS adjusted #ACR25 @RheumNow @ACRheum #abst0216 https://t.co/CkG6gpiCw3

https://x.com/Janetbirdope/status/1982521250959565160/photo/1

Two Jacks, One mission 🤓 Head on to the booth and get a chance to meet either one of them (both if you’re lucky, like me!) Continue tuning in for coverage of #ACR25 by the @RheumNow faculty and KOLs https://t.co/Y2pS8CpoH5

https://x.com/RHEUMarampa/status/1982518851050037697/photo/1

CE study BEL vs csDMARDs in TriNetX Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analysis Pretty surprising given mediocre results from BLISS RCTs, but strong research group & lotsa fancy stats Do you believe it? #ACR25 @RheumNow Abstr#0804 https://t.co/Yex98EYDjP

#ACR25 Abstr#802 In #SLE pts with CLASI-A ≥8, pooled post-hoc analysis of Phase 2 RCT showed enpatoran, oral small molecule toll-like receptor 7/8-i impoved cutaneous response vs PBO as early as WK4. First-in-class promising therapy & warrant investigation in Phase 3 @RheumNow https://t.co/rn6NXdiGjD

Urinary proteomics reveals promising biomarkers for ankylosing spondylitis. PIK3IP1 & SDC1 levels were significantly elevated in AS patients, showing strong diagnostic performance (AUCs: 0.852 & 0.875). Combined with AMY1A, the multiplex panel reached an AUC of 0.973. Abstract https://t.co/YUulKFqj8V

https://x.com/synovialjoints/status/1982515068551024689/photo/1

Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes -Diabetic nephropathy -Stage 3–5 CKD and reduced risk compared to TNFi treated and bionaive pts Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T

The benefits of exercise has been proven for most rheumatic diseases, and there are lots of good reasons why #ACR25 Brian Andonian @RheumNow https://t.co/IEErXL6ynL

https://x.com/drdavidliew/status/1982514009577570359/photo/1

What is my risk of developing proteinuria? Hopkins Lupus Cohort developed a risk score predicting 10-year risk of new-onset proteinuria after SLE dx (n=1,418) @RheumNow #ACR25 https://t.co/Z0zPrG2NJ3

https://x.com/AkhilSoodMD/status/1982512551347859921/photo/1

#ACR25 Abstr#801 Post-hoc analysis of Phase 2 RCT showed longer duration on Ianalumab (IAN) is beneficial. More #SLE pts achieved LLDAS or DORIS remission and GC taper in IAN in blinded 28-wk phase + open label IAN for the next 24-week group vs PBO-Open Label IAN @RheumNow https://t.co/I1Ugfj3BBl

https://x.com/Yuz6Yusof/status/1982512157893050797/photo/1

A retrospective study from Spain assessed the relationship bet HPV infxn & biologic tx in SLE pts 🔅 Prevalence of HPV 9.9% 🔅 No significant assocs bet HPV infxn, biologic tx, SLE-related dse variables & HPV RF progression Still, emphasize HPV screening #ACR25 @RheumNow Abs0659 https://t.co/1YusM1nYPr

https://x.com/RHEUMarampa/status/1982511293178491235/photo/1

#0777 Big news for VEXAS! 🎯 The first validated disease activity index (VEXAS-DAI) has been developed via international Delphi consensus. A 12-domain, 40-point tool to standardise assessment & power trials in this complex syndrome. Validation underway! @RheumNow #ACR25 https://t.co/DSeHb7eNeV

https://x.com/DrMiniDey/status/1982510034925015534/photo/1

Redefining When to Biopsy the Kidney in Patients with SLE # Petri et al. ACR 2025 - Lupus nephritis may be seen in lower proteinuria too (69%) Happy to share similar results from our study-Padiyar S, As C, Gowri M, Mathew J. Lupus. 2024;33(13):1511-1517. @RheumNow

Topics

All News

New Gout Therapies Show Promise in Phase III Trials

ACR Convergence 2025 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases

Do you get our email newsletter?